Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA To Ask Advisory Committees To Review Phase IV Safety Trial Designs

Executive Summary

FDA is preparing to take proposals for large post marketing studies to its drug advisory committees to solicit outside advice and counsel on the design and term of the new mandatory studies

You may also be interested in...

IL-1 Beta Beckons In Type 2 Diabetes and Potentially, Cardiovascular Disease

The IL-1 receptor has long been a target for autoimmune therapies. Now, data are emerging using several drugs, notably IL-1 beta antibodies, which support the general notion that blocking the IL-1 pathway could be useful in treating diabetes, particularly in patients at risk of cardiovascular disease. Indeed, one recent paper suggests that it could even be a therapeutic strategy to prevent heart failure after acute AMI.

The REMS Ramp Up: FDA Using New Safety Tools More Frequently In Year Two

FDA is using its new Risk Evaluation and Mitigation Strategy authorities much more frequently in the second year since the law took effect

CDER Offices Go Public With “Fundamental Disagreement” Over Avandia

Political pressure from FDA outsiders interested in improving drug safety oversight may have backfired, resulting in an embarrassing advisory committee meeting for the agency. The July 30 review of a cardiovascular safety signal for GlaxoSmithKline's diabetes drug Avandia became a forum to play out another controversy between the Office of New Drugs and the Office of Surveillance and Epidemiology





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts